<DOC>
	<DOCNO>NCT00713323</DOCNO>
	<brief_summary>The purpose study assess safety tolerability long term therapy Sativex® relieve neuropathic pain .</brief_summary>
	<brief_title>A Study Compare Safety Tolerability Sativex® Patients With Neuropathic Pain .</brief_title>
	<detailed_description>This 38 week , multicentre , open label ( Part A ) follow-on study evaluate , maintenance effect , development tolerance exposure , safety , Sativex® treatment subject neuropathic pain . The study provide continued availability Sativex® subject complete precede double-blind neuropathic pain study . Consenting , eligible subject participate previous GW Pharma Ltd ( GW ) randomise , placebo-controlled clinical study enter study ( Visit 1 , Day 0 ) commence dose . Study visit take place Week 2 ( Visit 2 , Day 14 ) , Week 14 ( Visit 3 , Day 98 ) , Week 26 ( Visit 4 , Day 182 ) . Subjects return centre end treatment visit week 38 ( Visit 5 , Day 266 ) . All subject receive Sativex® . This follow five week randomised-withdrawal phase ( Part B ) subset subject . An end study visit take place 28 day Visit 5 ( 5b 5c ) withdrawal study .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>Had participate GW clinical study investigate effect Sativex® peripheral neuropathic pain complete study . This must within last seven day Had comply study requirement precede GW parent RCTs , include completion diary card study questionnaire Had show tolerability study medication precede GW study Was expect , opinion investigator , gain clinical benefit receive Sativex® therapy Ability ( investigator opinion ) willingness comply study requirement , include completion diary card study questionnaires Agreement responsible authority ( applicable individual country ) , primary care physician , consultant , appropriate , notified participation study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition Known suspect history alcohol substance abuse History epilepsy recurrent seizure Known suspect hypersensitivity cannabinoids excipients study medication Evidence cardiomyopathy Experienced myocardial infarction clinically relevant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put subject risk clinically relevant arrhythmia myocardial infarction QT interval ; &gt; 450 m ( male ) &gt; 470 m ( female ) Visit 1 Secondary tertiary AV block sinus bradycardia ( HR &lt; 50bpm unless physiological ) sinus tachycardia ( HR &gt; 110bpm ) Visit 1 Diastolic blood pressure &lt; 50 mmHg &gt; 105 mmHg sit position rest five minute prior measurement Visit 1 Impaired renal function i.e. , creatinine clearance lower 50ml/min Visit 1 indicative renal impairment Significantly impair hepatic function , Visit 1 , Investigator 's opinion Female subject child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter If female , pregnant lactating , plan pregnancy course study three month thereafter Received IMP within 12 week Visit 1 ( except prerequisite study medication GW parent RCTs ) Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study subject 's ability participate study Following physical examination , subject abnormality , opinion investigator , would prevent subject safely participate study . Intention donate blood study Previous randomisation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>Peripheral Neuropathy</keyword>
</DOC>